Brief: SSY Group Says Safinamide Mesylate Obtains First Bulk Drug Approval In China
26/05/2026 02:11
May 26 (Reuters) - SSY Group Ltd 2005.HK: SAFINAMIDE MESYLATE OBTAINS FIRST BULK DRUG APPROVAL IN CHINA APPROVAL FOR REGISTRATION FROM CHINA'S NMPA Further company coverage: 2005.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SSY
See all newsBrief: SSY Group Receives NMPA China Approval For Sodium Cromoglicate Eye Drops 2%
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth